152 related articles for article (PubMed ID: 3967188)
1. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma.
Radl J; Croese JW; Zurcher C; van den Enden-Vieveen MH; Brondijk RJ; Kazil M; Haaijman JJ; Reitsma PH; Bijvoet OL
Cancer; 1985 Mar; 55(5):1030-40. PubMed ID: 3967188
[TBL] [Abstract][Full Text] [Related]
2. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.
Dallas SL; Garrett IR; Oyajobi BO; Dallas MR; Boyce BF; Bauss F; Radl J; Mundy GR
Blood; 1999 Mar; 93(5):1697-706. PubMed ID: 10029599
[TBL] [Abstract][Full Text] [Related]
3. Unwrapping microcomputed tomographic images for measuring cortical osteolytic lesions in the 5T2 murine model of myeloma treated by bisphosphonate.
N'Diaye M; Libouban H; Aguado E; Bouvard B; Audran M; Chappard D
Micron; 2015 Jan; 68():107-114. PubMed ID: 25464148
[TBL] [Abstract][Full Text] [Related]
4. Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model.
Libouban H; Moreau MF; Baslé MF; Bataille R; Chappard D
Bone; 2003 Sep; 33(3):283-92. PubMed ID: 13678768
[TBL] [Abstract][Full Text] [Related]
5. The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow.
Croese JW; Vas Nunes CM; Radl J; van den Enden-Vieveen MH; Brondijk RJ; Boersma WJ
Br J Cancer; 1987 Nov; 56(5):555-60. PubMed ID: 3426918
[TBL] [Abstract][Full Text] [Related]
6. Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
Søe K; Plesner T; Jakobsen EH; Hansen CT; Jørgensen HB; Delaissé JM
J Bone Miner Res; 2013 Aug; 28(8):1738-50. PubMed ID: 23427025
[TBL] [Abstract][Full Text] [Related]
7. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma.
Abildgaard N; Rungby J; Glerup H; Brixen K; Kassem M; Brincker H; Heickendorff L; Eriksen EF; Nielsen JL
Eur J Haematol; 1998 Aug; 61(2):128-34. PubMed ID: 9714526
[TBL] [Abstract][Full Text] [Related]
8. Aredia: the once-monthly infusion for the treatment of bone metastases.
Lipton A
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S1-5. PubMed ID: 9801852
[TBL] [Abstract][Full Text] [Related]
9. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.
Morton AR; Cantrill JA; Pillai GV; McMahon A; Anderson DC; Howell A
BMJ; 1988 Sep; 297(6651):772-3. PubMed ID: 3142542
[No Abstract] [Full Text] [Related]
10. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Terpos E; Dimopoulos MA; Berenson J
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
[TBL] [Abstract][Full Text] [Related]
11. [Bisphosphonates in the therapy of cancer patients].
Jantunen E; Kumpulainen E
Duodecim; 1999; 115(1):27-32. PubMed ID: 11830857
[No Abstract] [Full Text] [Related]
12. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.
Lee OL; Horvath N; Lee C; Joshua D; Ho J; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Talaulikar D; Brown R; Augustson B; Ling S; Jaksic W; Gibson J; Kalff A; Johnston A; Kalro A; Ward C; Prince HM; Zannettino A
Intern Med J; 2017 Aug; 47(8):938-951. PubMed ID: 28782211
[TBL] [Abstract][Full Text] [Related]
13. Anti-myeloma activity of pamidronate in vivo.
Dhodapkar MV; Singh J; Mehta J; Fassas A; Desikan KR; Perlman M; Munshi NC; Barlogie B
Br J Haematol; 1998 Nov; 103(2):530-2. PubMed ID: 9827929
[TBL] [Abstract][Full Text] [Related]
14. Osteoclast recruitment in mice is stimulated by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate.
Marshall MJ; Holt I; Davie MW
Calcif Tissue Int; 1993 Jan; 52(1):21-5. PubMed ID: 8453501
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
[TBL] [Abstract][Full Text] [Related]
16. [Effect of bisphosphonate on myeloma bone disease].
Abe M; Matsumoto T; Kosaka M
Rinsho Ketsueki; 2002 May; 43(5):349-52. PubMed ID: 12096484
[No Abstract] [Full Text] [Related]
17. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
18. [Establishment of a model to evaluate inhibition of bone resorption induced by bladder tumor (MBT-2) in mice].
Nishijima Y; Nemoto R; Koiso K
Nihon Hinyokika Gakkai Zasshi; 1990 May; 81(5):694-700. PubMed ID: 2376925
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials of bisphosphonates in multiple myeloma.
Mahindra A; Pozzi S; Raje N
Clin Adv Hematol Oncol; 2012 Sep; 10(9):582-7. PubMed ID: 23073123
[TBL] [Abstract][Full Text] [Related]
20. The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
Shipman CM; Vanderkerken K; Rogers MJ; Lippitt JM; Asosingh K; Hughes DE; Van Camp B; Russell RG; Croucher PI
Br J Haematol; 2000 Oct; 111(1):283-6. PubMed ID: 11091214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
